Artificial intelligence (AI) is taking over the world. Individuals and corporations are implementing the technology in their day-to-day lives and operations; governmental institutions are doing the same. The U.S. Food and Drug Administration (FDA) recently announced it would phase out animal testing in drug development in favor of other methods, including AI-based testing.That's good news for Recursion Pharmaceuticals (RXRX 3.67%), a biotech company that's already pioneering the use of AI in drug developmen ...

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics. Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science a ...

Recursion Pharmaceuticals (RXRX) shares soared 27.7% in the last trading session to close at $5.76. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.1% loss over the past four weeks.Earlier this month, the company announced that it has dosed the first patient in its early-stage study of investigational candidate, REC-3565, for treating relapsed or refractory (R/R) B-cell lymphomas. REC-3565 is a selective MALT1 inhibitor develo ...

Core Insights - Recursion Pharmaceuticals (RXRX) has initiated dosing for the first patient in its early-stage study of REC-3565, aimed at treating relapsed or refractory B-cell lymphomas, utilizing its AI-driven Recursion OS platform [1][2] - The unique mechanism of REC-3565 is anticipated to reduce the risk of drug-drug interactions and hyperbilirubinemia, potentially allowing for safer dose escalation and improved clinical efficacy [2] - RXRX's shares have decreased by 41.3% year-to-date, contrasting with a 14.6% decline in the industry [3] Pipeline Development - The Phase I EXCELERIZE study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of REC-3565, structured in two parts: monotherapy and combination therapy [5] - REC-3565 is positioned to address the limited treatment options available for relapsed or refractory B-cell lymphomas, with the potential to enhance patient outcomes [6] Other Pipeline Candidates - RXRX is also developing REC-994 for cerebral cavernous malformation (CCM), affecting approximately 360,000 symptomatic individuals in the US and EU, with a broader global impact potentially exceeding one million patients [7] - The company has met primary safety endpoints in mid-stage studies for REC-994 and plans to consult with the FDA for further development pathways [8] - Other mid-stage candidates include REC-2282 (neurofibromatosis type II), REC-4881 (familial adenomatous polyposis), REC-3964 (recurrent Clostridioides difficile infection), and REC-1245 (biomarker-enriched solid tumors and lymphoma) [9] Collaborations - RXRX has established collaboration agreements with major pharmaceutical companies such as Roche, Bayer, Merck, and Sanofi to develop candidates for various oncology indications [10]

About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstra ...

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed or refractor ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bi ...

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $6.48, down 1.52% from the previous trading session, underperforming the S&P 500 which lost 0.22% [1] - The stock has decreased by 39.47% over the past month, significantly lagging behind the Medical sector's loss of 0.63% and the S&P 500's loss of 7.48% [1] Upcoming Financial Results - The upcoming EPS for Recursion Pharmaceuticals is projected at -$0.44, indicating a 12.82% decline compared to the same quarter last year [2] - Revenue is expected to be $20.15 million, reflecting a 46.12% increase from the equivalent quarter last year [2] Full-Year Estimates - Zacks Consensus Estimates forecast earnings of -$1.41 per share and revenue of $88.55 million for the full year, representing year-over-year changes of +16.57% and +50.5%, respectively [3] Analyst Estimates - Recent changes to analyst estimates for Recursion Pharmaceuticals indicate a positive outlook on the company's business operations and profit generation capabilities [4] - The Zacks Rank system, which reflects these estimate changes, provides a rating system that can help investors make informed decisions [5] Zacks Rank and Industry Performance - Recursion Pharmaceuticals currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.18% over the past month [6] - The Medical - Drugs industry, part of the Medical sector, has a Zacks Industry Rank of 85, placing it in the top 34% of over 250 industries [7]

Recursion Pharma (RXRX) shares have plunged 37.1% in the past month compared with the industry’s 1.4% decline. The company has also underperformed in the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below both its 50-day and 200-day moving averages.RXRX Stock Underperforms the Industry, Sector & the S&P 500Image Source: Zacks Investment ResearchThe recent decline in Recursion Pharma's stock can be attributed to a combination of macroeconomic c ...

Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion’s Board of Directors, effective as of March 15th.“I am delighted to welcome El ...